CYP2C19 and transient ischemic attack: In patients allergic to Clopidogrel and in carriers of a CYP2C19 loss of function allele, Ticagrelor might be an alternative according to findings of the Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA [acetylsalicylic acid] for Prevention of Stroke and Death (THALES) trial (109–112).